Open AccessA Case of Steatocystoma Multiplex in a Psoriatic Patient during Treatment with Anti-IL-12/23
Author(s) -
Claudio Marasca,
Matteo Megna,
Marianna Donnarumma,
Giuseppina Fontanella,
Eleonora Cinelli,
Gabriella Fabbrocini
Publication year - 2020
Publication title -
skin appendage disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.773
H-Index - 13
eISSN - 2296-9195
pISSN - 2296-9160
DOI - 10.1159/000507657
Subject(s) - missense mutation , ustekinumab , demodex , dermatology , medicine , genodermatosis , psoriasis , morphea , gene , mutation , pathology , biology , disease , genetics , lichen sclerosus , infliximab , botany , mite
Steatocystoma multiplex (SM) is an autosomal dominant disorder developing in adolescence or early adult age. The occurrence of multiple asymptomatic cutaneous cysts on the axillae, groin, trunk, and limbs characterizes the disease. SM is associated with a missense mutation in the keratin 17 gene (KRT17), a gene encoding for a type I intermediate filament (keratin 17 [K17]), mainly expressed in the epithelial appendages (hair follicles and sebaceous glands). Here, we report a case of appearance of multiple steatocystomas in a psoriatic patient during ustekinumab treatment, an interleukin (IL)-12/IL-23 inhibitor. Our hypothesis is that ustekinumab could have unmasked a potential genetic predisposition to SM by reducing the expression of interferon-γ and IL-17/IL-22 and consequently acting on the K17 pathway.